[Form 4] QuidelOrtho Corp Insider Trading Activity

Rhea-AI Filing Summary

QuidelOrtho (QDEL) reported insider equity activity by EVP of R&D & CTO Jonathan P. Siegrist. On 10/15/2025, 18,656 restricted stock units converted into common stock at $0 per unit. To cover taxes, 6,676 shares were withheld by the issuer at a price of $27.31.

Following these transactions, Siegrist directly holds 11,980 shares of common stock. He also holds 37,314 RSUs that will vest in equal installments on October 15, 2026 and October 15, 2027. Each RSU represents the right to receive one share of QuidelOrtho common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Siegrist Jonathan Philip

(Last) (First) (Middle)

9975 SUMMERS RIDGE ROAD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QuidelOrtho Corp [ QDEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP of R&D & CTO

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/15/2025		A		18,656(1)	A	$0	18,656	D
Common Stock	10/15/2025		F		6,676(2)	D	$27.31	11,980	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(3)	10/15/2025		M			18,656	(4)	(4)	Common Stock	18,656	$0	37,314	D

Explanation of Responses:

1. Reflects release of restricted stock units that were previously reported on a Form 3.

2. Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units.

3. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.

4. 18,656 shares vested on October 15, 2025; the remaining 37,314 shares will vest in equal installments on October 15, 2026 and October 15, 2027.

Remarks:

	/s/ Euna Greene, attorney-in-fact for Jonathan P. Siegrist	10/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did QuidelOrtho (QDEL) disclose in this Form 4?

An executive had 18,656 RSUs vest on 10/15/2025 and 6,676 shares were withheld to satisfy tax obligations.

How many QuidelOrtho (QDEL) shares does the insider hold after the transactions?

The reporting person directly holds 11,980 common shares after the reported transactions.

What was the tax withholding price on the QuidelOrtho (QDEL) shares?

Shares were withheld at $27.31 per share to satisfy tax withholding obligations.

How many RSUs remain for the QuidelOrtho (QDEL) executive and when do they vest?

There are 37,314 RSUs remaining, vesting in equal installments on October 15, 2026 and October 15, 2027.

What does each RSU represent for QuidelOrtho (QDEL)?

Each RSU represents the right to receive one share of QuidelOrtho common stock.

Who is the reporting person in this QuidelOrtho (QDEL) filing?

The reporting person is Jonathan P. Siegrist, EVP of R&D & CTO.